Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II imatinib study in inoperable medullary thyroid carcinoma
NL-OMON21527Phase 2Active, not recruiting
- Sponsor
- N/A
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in Medullary Thyroid Cancer (MTC), sponsored by N/A. Primary endpoint: Objective response rate. Started Jul 2003; status: active, not recruiting.
02
Drugs
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON21527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21527.